Date: 2014-06-18
Type of information: Pipeline acquisition
Compound: melanocortin receptors (MCRs) programme
Company: MRC Technology (UK) Pfizer (USA - NY)
Therapeutic area:
Type agreement:
Action mechanism:
Disease:
Details: * On June 18, 2014, the technology transfer organisation MRC Technology announced that it has sold to Pfizer its melanocortin receptors (MCRs) programme, which includes a set of small molecules. Targets for these small molecules came to the attention of MRC Technology from Mauro Perretti, Professor of Immunopharmacology at Queen Mary University of London (QMUL), and MRC Technology ran a screening programme in collaboration with QMUL. MCRs have a wide and varied distribution throughout the body, being found in the central nervous system, periphery and immune cells.
Financial terms: The undisclosed financial consideration received by MRC Technology from this transaction with Pfizer will be shared with QMUL’s William Harvey Research Institute, of which Professor Perretti is Co-Director. Under MRC Technology’s not-for-profit collaborative model, revenue retained from this transaction will be reinvested to support other collaborative programmes within its drug discovery labs.
Latest news:
